Back to Agenda
Session 4A: Considerations for Expanding Proactive Communications by Biopharmaceutical Manufacturers to Population Health Decision Makers
Session Chair(s)
Soumi Saha, JD, PharmD
Assistant Director of Pharmacy & Regulatory Affairs
Academy of Managed Care Pharmacy (AMCP), United States
This session will provide a landscape of the current requirements for proactive communications of HCEI, highlighting the challenges and barriers within the existing infrastructure. This panel discussion will also provide key stakeholder perspectives on why access to HCEI is critical to better care for patients and discuss possible solutions to enable better and timelier communications between biopharmaceutical manufacturers and population health decision makers. Potential implications for patients will also be discussed. Finally, this session will discuss the implications of new draft guidance released by the FDA governing manufacturer communications with payors.
Speaker(s)
Panelist
Michelle Drozd
Pharmaceutical Research and Manufacturers of America (PhRMA), United States
Deputy Vice President, Policy & Research
Panelist
Amy Duhig, PhD
Xcenda, United States
Sr. Director, Outcomes Research, Global Health Economics and Outcomes Research
Panelist
Morgan Romine, MPA
Duke University, United States
Chief of Staff
Have an account?